Michael Fishman, MD
Interventional Pain Medicine · Lebanon, PANPI 1841429156
Payments from drug & device makers
Across 1,673 payments — averaging $923.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1.2M
- Abbott$98K
- MML US, Inc.$78K
- Aurora Spine, Inc.$46K
- Nevro Corp.$22K
- Biotronik Inc.$15K
- plus $35K from 47 others
Across 6 payments — averaging $979.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$6K
- Saluda Medical Americas, Inc.$274
What the payments were for
- Royalty or licence$21,2663%
- Consulting fees$105,05016%
- Speaking & faculty fees$430,13464%
- Travel & lodging$81,26312%
- Food & beverage$32,3595%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$230,119
- INTELLIS$148,622
- ZIP$46,420
- VANTA ADAPTIVESTIM$39,292
- ReActiv8$27,656
- RESTORE$26,382
- ADAPTIVESTIM$21,684
- Senza Spinal Cord Stimulation System$21,075
- SYNCHROMED$11,620
- Proclaim Family of SCS IPGs$7,672
- XTAMPZA$4,276
- BELBUCA$4,170
- Intracept$3,196
- Neuromodulation Dspsbls and Accs$3,033
- OPTIMIZER$2,709
- RESTORESENSORSURESCAN$2,573
- Inflate FX$2,450
- Prospera$2,017
- Vanta$1,287
- mild Device Kit$1,225
How this compares
$1,544,275 in reported general payments places this provider in the 95th percentile of 59 interventional pain medicine providers in Pennsylvania.
See all interventional pain medicine providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 59 | $1,099 |
| Morphine Sulfate ErMorphine Sulfate | 16 | $458 |
| Gabapentin | 33 | $272 |
| Methadone Hcl | 13 | $196 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $190 |
| Tramadol Hcl | 19 | $62 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Lebanon
- David ProvenzanoSewickley$1.2M
- Fred KhaloufAltoona$490K
- Keith ZoraState College$268K
- Michael FarrellPittsburgh$23K
- Michael FurmanYork$20K
- Farshad RashidianWest Chester$19K
- Chad MetzgerDarby$14K
- Jorge Rivero-BecerraPittsburgh$12K
- James BresnahanSpringfield$12K
- Jonathan SchollIndiana$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.